Results 61 to 70 of about 1,671,061 (305)

Fluvoxamine combined with lenvatinib enhances anti-hepatocellular carcinoma immunity by promoting M1 macrophage and T-cell infiltration

open access: yesScientific Reports
This study aimed to investigate the synergistic antitumor activity of fluvoxamine combined with lenvatinib against hepatocellular carcinoma (HCC). Lenvatinib remains an approved targeted therapy for HCC but has limited single-agent efficacy with frequent
Zhi Zheng   +10 more
doaj   +1 more source

CBX4 facilitates EV71 replication by SUMOylation and stabilizing 3D polymerase

open access: yesFrontiers in Microbiology
Enterovirus 71 (EV71) is a primary etiological agent of hand-foot-mouth disease (HFMD) in children under 5 years of age and can cause severe neurological disorders even death.
Rui Su   +6 more
doaj   +1 more source

Immune clusters associated with immune checkpoint molecules.

open access: yes, 2020
(A) Evaluation of the immune checkpoint molecules expression in different immune clusters; (B) IFNG expression in different immune clusters; (C) Evaluation of the TMB in different immune clusters in the TCGA cohort; (D) Correlation matrix of all 22 TIICs
Min Jiao (2221057)   +11 more
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

The role of Clostridium butyricum and its metabolites in modulating gut mucosal immunity: implications for viral infections and inflammatory diseases

open access: yesFrontiers in Immunology
With global viral emergence and increasing antiviral resistance, there is an urgent need for innovative immunomodulatory strategies. Gut microbiota modulation has gained attention as a promising therapeutic approach. Clostridium butyricum (C.
Shaoju Qian   +14 more
doaj   +1 more source

Bell's palsy during rechallenge of immune checkpoint inhibitor

open access: yesIJU Case Reports, 2023
Introduction The peripheral nervous system is one of the target organs of immune‐related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features ...
Kohji Takemura   +9 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

The CD47-SIRPα Immune Checkpoint

open access: yesImmunity, 2020
The cytotoxic activity of myeloid cells is regulated by a balance of signals that are transmitted through inhibitory and activating receptors. The Cluster of Differentiation 47 (CD47) protein, expressed on both healthy and cancer cells, plays a pivotal role in this balance by delivering a "don't eat me signal" upon binding to the Signal-regulatory ...
Meike E.W. Logtenberg   +2 more
openaire   +3 more sources

Immune Checkpoint Inhibitor Toxicities [PDF]

open access: yesMayo Clinic Proceedings, 2019
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been
Julian A. Marin-Acevedo   +2 more
openaire   +2 more sources

Immune-Checkpoint Blockade Therapy in Lymphoma

open access: yes, 2020
Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on ...
Yosuke Minami   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy